GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lowered its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 45.3% in the third quarter, Holdings Channel reports. The institutional investor owned 30,451 shares of the company’s stock after selling 25,237 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in GE HealthCare Technologies were worth $2,858,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Research Global Investors grew its holdings in GE HealthCare Technologies by 5.2% during the 1st quarter. Capital Research Global Investors now owns 53,991,923 shares of the company’s stock worth $4,908,406,000 after acquiring an additional 2,647,204 shares in the last quarter. Vanguard Group Inc. grew its stake in GE HealthCare Technologies by 9.2% in the first quarter. Vanguard Group Inc. now owns 48,519,340 shares of the company’s stock worth $4,410,893,000 after purchasing an additional 4,107,746 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in GE HealthCare Technologies by 18.0% in the second quarter. The Manufacturers Life Insurance Company now owns 1,245,961 shares of the company’s stock valued at $97,088,000 after buying an additional 189,956 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in GE HealthCare Technologies by 2.1% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,025,320 shares of the company’s stock valued at $93,212,000 after buying an additional 20,776 shares in the last quarter. Finally, Stonegate Investment Group LLC lifted its holdings in GE HealthCare Technologies by 1.0% during the 3rd quarter. Stonegate Investment Group LLC now owns 979,649 shares of the company’s stock worth $91,940,000 after buying an additional 9,572 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Thomas J. Westrick sold 2,750 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $80.78, for a total transaction of $222,145.00. Following the completion of the sale, the chief executive officer now directly owns 17,509 shares of the company’s stock, valued at approximately $1,414,377.02. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

GEHC has been the subject of a number of research analyst reports. BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Wednesday, September 18th. Wells Fargo & Company boosted their target price on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a research note on Thursday. Stifel Nicolaus raised their price target on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Evercore ISI lifted their price target on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. began coverage on shares of GE HealthCare Technologies in a research note on Monday, September 9th. They set a “neutral” rating and a $90.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GE HealthCare Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $94.36.

GE HealthCare Technologies Stock Down 0.5 %

GEHC opened at $86.95 on Friday. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.82. GE HealthCare Technologies Inc. has a 12 month low of $66.39 and a 12 month high of $94.55. The stock’s 50 day moving average price is $88.61 and its 200 day moving average price is $83.45. The stock has a market cap of $39.71 billion, a P/E ratio of 23.89, a P/E/G ratio of 3.26 and a beta of 1.18.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The business had revenue of $4.86 billion during the quarter, compared to analysts’ expectations of $4.87 billion. During the same period last year, the firm posted $0.99 earnings per share. The business’s revenue was up .9% on a year-over-year basis. As a group, research analysts predict that GE HealthCare Technologies Inc. will post 4.26 earnings per share for the current year.

GE HealthCare Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Friday, October 18th will be issued a $0.03 dividend. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.14%. GE HealthCare Technologies’s payout ratio is currently 3.30%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.